Welcome!

News Feed Item

The Leukemia & Lymphoma Society Awards $12.6 Million in Research Grants in Six Critical Areas of Unmet Medical Need

WHITE PLAINS, N.Y., Jan. 6, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) has awarded 21 new grants representing a total investment of $12.6 million to tackle six areas of high unmet medical need in the blood cancers.

In response to requests for proposals (RFPs) from researchers in these six critical areas, LLS has awarded these grants under its Translational Research Program (TRP), an initiative designed to help accelerate the movement of promising discoveries from the lab to the clinic. Each grant is for a three-year duration with a total value of $600,000.

The RFPs mark LLS's proactive approach to addressing the challenge of improving outcomes for cancer patients with particularly urgent needs. The focus of the TRP grants, and the grant recipients are as follows:

  • New immunotherapeutics for patients with acute myelogenous leukemia (AML):

    • David Avigan, M.D., Beth Israel Deaconess Medical Center. Clinical trial evaluating DC/AML fusion vaccine with PD1 blockade
    • Stephen Forman, M.D., Beckman Research Institute of the City of Hope. Adoptive therapy for AML using CAR123-transduced T cells
    • Dean Lee, M.D., Ph.D., University of Texas MD Anderson Cancer Center. Targeting NK cell immunotherapy against AML stem cells.
    • Ulrich Steidl, M.D., Ph.D., Albert Einstein College of Medicine of Yeshiva University. Targeting IL-1 receptor accessory protein in malignant stem cells in AML
    • Chengcheng Zhang, Ph.D., UT Southwestern Medical Center. Blocking immune inhibitory receptor LAIR1 for AML treatment

  • Novel therapeutics for patients with non-cutaneous T-cell malignancies:

    • Thomas Loughran, M.D., The Pennsylvania State University College of Medicine. Targeting JAK/STAT and NF-kB pathways in large granular lymphocytic leukemia
    • David Wiest, Ph.D., Fox Chase Cancer Center, Role of ER stress responses in pathogenesis and treatment of T-cell acute lymphocytic leukemia
    • Javeed Iqbal, Ph.D., Board of Regents of the University of Nebraska Medical Center. Somatic mutations and epimutations in peripheral T-cell lymphoma

  • Introduction of novel agents in the treatment of patients with diffuse large B-cell lymphom(DLBCL) and mantle cell lymphoma(MCL):

    • Robert Baiocchi, M.D., Ph.D., The Ohio State University Research Foundation. Targeting PRMT5 expression in DLBCL and MCL
    • Leandro Cerchietti, M.D., Joan & Sanford I. Weill Cornell Medical College of Cornell University. EIF4E targeted therapy in lymphomas
    • Ari Melnick, M.D., Joan & Sanford I. Weill Cornell Medical College of Cornell University. Rational translational of EZH2 targeted therapy
    • Alessandra Pernis, M.D., The Hospital for Special Surgery. Novel signaling pathways in DLBCL
    • James Rubenstein, M.D., Ph.D., The Regents of the University of California, San Francisco. Molecular targets for high-risk primary CNS lymphoma
    • John Timmerman, M.D., The Regents of the University of California, Los Angeles. PD-1/PD-L1 blockade plus kinase inhibitor therapies for B cell lymphomas

  • Therapies for patients with myelodysplastic syndromes(MDS) who have failed hypomethylating agents:

    • Maria Figueroa, M.D., University of Michigan Health System, Epigenetic markers of sensitivity and resistance to hypomethylating agents

  • Therapies for new targets such as bromodomains, methylation and other epigenetic approaches for patients with high-risk myeloma:

    • Xiu-Bao Chang, Ph.D., Mayo Clinic Arizona. Immunomodulatory drugs target cereblon and its downstream substrates
    • Constantine Mitsiades, M.D., Ph.D., Dana-Farber Cancer Institute. Individualizing myeloma treatment with BET bromodomain inhibitors

  • Research that addresses long-term and late effects of blood cancer therapies:

    • Mukta Arora, M.D., Regents of the University of Minnesota, Twin Cities. Biomarkers of frailty and its impact on geriatric HSCT outcomes
    • Seth Corey, M.D., Northwestern UniversityChicago campus. Development of an oral anti-fibrotic drug for patients with myelofibrosis
    • Patricia Gallagher, Ph.D., Wake Forest University Health Sciences. Prevention of doxorubicin-induced cardiotoxic late effects by Ang-(1-7)
    • Matthew Matasar, M.D., Memorial Sloan-Kettering Cancer Center. Tissue and functional assessment of myocardial injury in HL survivors

LLS also announced the awarding of an additional 20 TRP grants not related to the RFPs, totaling $11.4 million, to scientists working in other areas of blood cancer research.

"The translation of research discoveries in the laboratory to the patient's bedside for the treatment of blood cancer is a central part of the mission of LLS," said Lee Greenberger, Ph.D., LLS chief scientific officer. "By taking a strategic, proactive approach, LLS is directing grant funds with the intent to accelerate the advancement of breakthrough therapies and provide the best quality of life for our patients."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif
(914) 821-8958
[email protected] 
www.LLS.org

 

SOURCE The Leukemia & Lymphoma Society

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
There is an ever-growing explosion of new devices that are connected to the Internet using “cloud” solutions. This rapid growth is creating a massive new demand for efficient access to data. And it’s not just about connecting to that data anymore. This new demand is bringing new issues and challenges and it is important for companies to scale for the coming growth. And with that scaling comes the need for greater security, gathering and data analysis, storage, connectivity and, of course, the...
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, will show how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningfu...
Many private cloud projects were built to deliver self-service access to development and test resources. While those clouds delivered faster access to resources, they lacked visibility, control and security needed for production deployments. In their session at 18th Cloud Expo, Steve Anderson, Product Manager at BMC Software, and Rick Lefort, Principal Technical Marketing Consultant at BMC Software, will discuss how a cloud designed for production operations not only helps accelerate developer...
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, will discuss how leveraging the Industrial Interne...
The IoTs will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm and share the must-have mindsets for removing complexity from the development proc...
The IETF draft standard for M2M certificates is a security solution specifically designed for the demanding needs of IoT/M2M applications. In his session at @ThingsExpo, Brian Romansky, VP of Strategic Technology at TrustPoint Innovation, will explain how M2M certificates can efficiently enable confidentiality, integrity, and authenticity on highly constrained devices.
Increasing IoT connectivity is forcing enterprises to find elegant solutions to organize and visualize all incoming data from these connected devices with re-configurable dashboard widgets to effectively allow rapid decision-making for everything from immediate actions in tactical situations to strategic analysis and reporting. In his session at 18th Cloud Expo, Shikhir Singh, Senior Developer Relations Manager at Sencha, will discuss how to create HTML5 dashboards that interact with IoT devic...
We're entering the post-smartphone era, where wearable gadgets from watches and fitness bands to glasses and health aids will power the next technological revolution. With mass adoption of wearable devices comes a new data ecosystem that must be protected. Wearables open new pathways that facilitate the tracking, sharing and storing of consumers’ personal health, location and daily activity data. Consumers have some idea of the data these devices capture, but most don’t realize how revealing and...
Struggling to keep up with increasing application demand? Learn how Platform as a Service (PaaS) can streamline application development processes and make resource management easy.
SYS-CON Events announced today that Ericsson has been named “Gold Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. Ericsson is a world leader in the rapidly changing environment of communications technology – providing equipment, software and services to enable transformation through mobility. Some 40 percent of global mobile traffic runs through networks we have supplied. More than 1 billion subscribers around the world re...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists will dis...
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
The increasing popularity of the Internet of Things necessitates that our physical and cognitive relationship with wearable technology will change rapidly in the near future. This advent means logging has become a thing of the past. Before, it was on us to track our own data, but now that data is automatically available. What does this mean for mHealth and the "connected" body? In her session at @ThingsExpo, Lisa Calkins, CEO and co-founder of Amadeus Consulting, will discuss the impact of wea...
If there is anything we have learned by now, is that every business paves their own unique path for releasing software- every pipeline, implementation and practices are a bit different, and DevOps comes in all shapes and sizes. Software delivery practices are often comprised of set of several complementing (or even competing) methodologies – such as leveraging Agile, DevOps and even a mix of ITIL, to create the combination that’s most suitable for your organization and that maximize your busines...